Opinion|Videos|July 15, 2024
Meeting Unmet Needs for Patients With RCC
Author(s)Martin H. Voss, MD
Martin H. Voss, MD, discusses the trajectory of the advanced renal cell carcinoma treatment landscape and provides clinical advice to community oncologists.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What are the current unmet needs for patients with renal cell carcinoma (RCC)?
Advertisement
Related to this article
Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.
The FDA has approved Omcazio, a capsule-based formulation of cabozantinib as a laurylsulfate salt, that demonstrated bioequivalence to the existing tablet.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
2
Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma
3
Sub-Q Amivantamab and Supportive Care Minimize Discontinuation in EGFR+ NSCLC
4
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
5